Belgian women’s health specialist Mithra Pharmaceuticals says the Canadian and US approvals and European endorsement received for its Estelle (estetrol/drospirenone) 15mg/3mg oral contraceptive mark a “turning point in its history,” following the firm’s previous successes with products including its Myring (etonogestrel/ethinylestradiol) generic rival to Merck & Co’s NuvaRing vaginal ring for which it expects to see further launches later this year.
Estetrol Approvals Mark 'Turning Point' For Mithra
Also Plans Further Launches Of Myring Generic Rival To NuvaRing
Recent Canadian, European and US endorsements of Mithra’s estetrol-based Estelle novel oral contraceptive mark a “turning point” for the Belgian firm, which has also seen success with its Myring generic rival to NuvaRing for which it expects to see further launches this year.
